Recs

8

This Week's 5 Smartest Stock Moves

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

If you're feeling down this week, take my hand as we go over some of the more uplifting headlines of the week. Yes, it wasn't all layoffs, missed earnings, and guidance knockdowns.

1. Mixing drug stocks
You know you're in the right sector when not one -- but two -- stocks receive buyout offers, from not two -- but three -- suitors.

CV Therapeutics (Nasdaq: CVTX  ) and Genentech (NYSE: DNA  ) were the blushing brides, receiving buyout offers at reasonable premiums. There have already been several huge deals brokered this year in the pharmaceuticals space. It won't be long before "take two buyouts and call me in the morning" becomes a daily prescription.

2. You've got bail
AOL finally has a new CEO, and he's actually turning heads. Google (Nasdaq: GOOG  ) advertising executive Tim Armstrong -- who watched over the search giant's North American and Latin American ad team -- is coming to AOL.

It couldn't come at a better time. AOL is treading water, but that water is Niagara Falls. AOL has been bleeding access subscribers for years, and its plan to make up for that with online advertising as a nonwalled garden has led to mixed results.

3. An Apple rumor a day
I've knocked Apple (Nasdaq: AAPL  ) for its reluctance in entering the hot netbook market, so I may as well pat its back when the rumor mill chatter is that a touchscreen netbook is in the works.

Naturally, a netbook with a fancy touchscreen and an Apple logo isn't going to come cheap. Apple may still miss the boat on what drew so many penny-pinching shoppers to dirt cheap netbooks over the holidays. However, if Apple is at least willing to throw its hat into this ring, as it seems to be doing, it's going to breathe new life into a brand that isn't as recession-resistant as shareholders would like to believe.

Apple retail sales presumably fell in January, and the economy didn't get any kinder in February. Without Steve Jobs around, the company has a big mock turtleneck to fill, and a huge splash in the booming netbook market should do it.

4. Staring at satellites
It's been a busy week for Sirius XM Radio (Nasdaq: SIRI  ) . It wasn't all good, as the company made this week's "Dumb" list after it refused to provide guidance (even for the current quarter) and posted quarterly results showing that it attracted less than half the net subscribers it had projected.

However, there are several welcome developments to earn the satellite radio operator a spot on this week's "Smart" list, too.

  • Sirius XM generated $31.8 million in pro forma adjusted income during the fourth quarter, for the first time in the company's history.
  • It finally made things official, announcing that an application would hit Apple's App Store during the second quarter. Apple iPhone and iPod touch owners will now be able to stream XM and Sirius.
  • The company's quarterly report showed some serious overhead trimming on various line items, vindicating the cost-saving synergies behind the merger in the first place.

5. One pill after the other
A few days before the CV Therapeutics and Genentech buyouts, Merck (NYSE: MRK  ) announced a $41.1 billion deal to acquire Schering-Plough (NYSE: SGP  ) .

The news broke on Monday morning, well before Wall Street's opening bell. It was such a big story that CNBC interrupted a live interview with Warren Buffett to break down the story.

No one will ever suggest that the Merck deal saved the market. Stocks actually fell on Monday, before going on to rally in each of the past three trading days. However, I think it helped set an upbeat tone. I was watching CNBC at the time, and Buffett was just starting to sell viewers on the long-term prospects of investing when – bam! -- a colossal deal drives it all home.

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

CV Therapeutics and Google are Motley Fool Rule Breakers selections. Apple is a Motley Fool Stock Advisor recommendation. Try any of our Foolish newsletters today, free for 30 days.

Longtime Fool contributor Rick Munarriz is an optimist at every turn. He's the inspiration for The Killers' "Mr. Brightside" song. Hdoes not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early. The Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 13, 2009, at 7:07 PM, wtfdidyousay wrote:

    aristotle - how DARE you! you have reached a new level of laziness/deception. check it out, people:

    This Week's 5 Dumbest Stock Moves:

    ----------------------------------

    http://www.fool.com/investing/high-growth/2009/03/13/this-we...

    and then this:

    This Week's 5 Smartest Stock Moves:

    ----------------------------------

    http://www.fool.com/investing/high-growth/2009/03/13/this-we...

    at this point it is patently obvious that these writers are injecting SIRI into their articles to get more clicks. the fact that SIRI is mentioned in both "the five dumbest stock moves" AND "the five smartest stock moves" on the SAME DAY demonstrates this. it removes ALL CREDIBILITY to any articles written by aristotle munarriz. its pitiful, really.

    i think that THIS is definitely worth pointing out to the moderators/editors over at motley fool. they need to know that their legitimacy as a source of financial news is being decimated.

  • Report this Comment On March 13, 2009, at 8:42 PM, gettingit wrote:

    Rick, the past few weeks you have had a vendetta against SIRI, however, this article shows that perhaps

    you are becoming a little more objective. Thank you and bravo-thsi is one way that Motley Fool will retain its readership-through objectivity!

  • Report this Comment On March 14, 2009, at 9:05 AM, wtfdidyousay wrote:

    UMMMMMMMMMMM......

    gettingit - did you read my post??

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 851316, ~/Articles/ArticleHandler.aspx, 2/11/2012 2:35:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 12,801.23 -89.23 -0.69%
S&P 500 1,342.64 -9.31 -0.69%
NASD 2,903.88 -23.35 -0.80%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/10/2012 4:00 PM
MRK $37.91 Down -0.24 -0.63%
Merck & Co., Inc. CAPS Rating: ****
SGP $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****
SIRI $2.15 Down -0.05 -2.05%
Sirius XM Radio CAPS Rating: **
GOOG $605.91 Down -5.55 -0.91%
Google CAPS Rating: ****
AAPL $493.42 Up +0.25 +0.05%
Apple CAPS Rating: ***
CVTX.DL $20.01 Down +0.00 +0.00%
CV Therapeutics CAPS Rating: **
DNA $94.97 Down +0.00 +0.00%
Genentech, Inc. CAPS Rating: ****

Advertisement